首页> 外文期刊>American Chemical Society >Radioimmunotherapy of Human Colon Cancer Xenografts with 131I-Labeled Anti-CEA Monoclonal Antibody
【24h】

Radioimmunotherapy of Human Colon Cancer Xenografts with 131I-Labeled Anti-CEA Monoclonal Antibody

机译:131I标记的抗CEA单克隆抗体对人结肠癌异种移植物的放射免疫治疗

获取原文
获取原文并翻译 | 示例
       

摘要

Radioimmunotherapy (RIT) is a promising approach for the treatment of a wide variety of malignancies. The aim of this study was to investigate the therapeutic efficacy of 131I-labeled anticarcinoembryonic antigen (CEA) monoclonal antibody CL58 in a human colon cancer mouse model. In vitro and in vivo characteristics of 125I-CL58 were evaluated in LS180 human colon cancer cells and the nude mouse model. 131I-CL58 was prepared and its in vivo therapeutic efficacy was tested. 125I-CL58 showed high affinity to LS180 cells, as well as high tumor uptake and long tumor retention in LS180 tumor xenografts. 131I-CL58 exhibited dose-dependent inhibition of LS180 tumor growth. With the excellent in vitro and in vivo characteristics, and the effective therapy for colon cancer in animal model, 131I-CL58 is a promising agent for RIT of CEA-positive tumors including colon cancer.
机译:放射免疫疗法(RIT)是一种治疗各种恶性肿瘤的有前途的方法。这项研究的目的是研究 131 I标记的抗癌胚抗原(CEA)单克隆抗体CL58在人结肠癌小鼠模型中的治疗效果。在LS180人结肠癌细胞和裸鼠模型中评估了 125 I-CL58的体外和体内特性。制备了 131 I-CL58,并对其体内治疗效果进行了测试。 125 I-CL58对LS180细胞具有高亲和力,并且在LS180肿瘤异种移植物中具有较高的肿瘤吸收率和长的肿瘤保留时间。 131 I-CL58对LS180肿瘤的生长具有剂量依赖性的抑制作用。 131 I-CL58具有出色的体外和体内特性,并能有效治疗动物模型中的结肠癌,是治疗包括结肠癌在内的CEA阳性肿瘤的有前途的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号